期刊文献+

抗血管生成小分子TKI在晚期结直肠癌中的进展 被引量:4

Progress of antiangiogenic tyrosine kinase inhibitors in advanced colorectal cancer
下载PDF
导出
摘要 血管生成是肿瘤发生发展的重要环节,晚期结肠癌治疗指南中,明确了抗血管生成靶向药物贝伐珠单抗在治疗中的重要地位。美国FDA根据CORRECT研究批准了小分子酪氨酸酶抑制剂\瑞戈非尼在晚期结直肠癌中的使用。TKI通过抗血管等作用显示了强有力的抗肿瘤作用。国内外针对抗血管生成小分子TKI开展了一系列临床试验,本文给予概述。 Angiogenesis is an important hallmark of cancer development and progression. The international consensus for colorec tal cancer (CRC) treatment acknowledged that bevacizumab, an anti-vascular endothelial growth factor A (VEGF-A) antibody, in combination with chemotherapy belongs to standard first-line treatment in CRC. Regorafenib has been approved by the US Food and Drug Administration based on the results from the CORRECT study. Multi- targeted ty:osine kinase inhibitors (TKI) have demonstrated significant antitumor effects in CRC through the inhibition of angiogeaetic. In this paper, we summarized a series of phase Ⅱ/ Ⅲ trials for anti-VEGF TKI.
出处 《中国研究型医院》 2017年第4期31-36,共6页 Chinese Research Hospitals
关键词 结直肠癌 抗血管生成 小分子酪氨酸激酶抑制剂(TKI) Colorectal cancer Anti-VEGF Tyrosine kinase inhibitors (TKI)
  • 引文网络
  • 相关文献

同被引文献45

引证文献4

二级引证文献15

;
使用帮助 返回顶部